Literature DB >> 25201015

Downregulation of FoxM1 inhibits proliferation, invasion and angiogenesis of HeLa cells in vitro and in vivo.

Hong Chen1, Yang Zou1, Hong Yang1, Jingjing Wang1, Hong Pan1.   

Abstract

FoxM1 is a specific transcription factor that has an important function in aggressive human carcinomas, including cervical cancer. However, the specific function and internal molecular mechanism in cervical cancer remain unclear. In this study, RNAi-mediated FoxM1 knockdown inhibited cell growth. This process also decreased the migration and invasion activities of HeLa cells in vitro. Downregulation of FoxM1 inhibited tumor growth and angiogenesis in vivo. In addition, the expressions of uPA, matrix metalloproteinase (MMP)-2, MMP-9 and VEGF were significantly decreased in vitro and in vivo. These results suggested that the inactivation of FoxM1 could be a novel therapeutic target for cervical cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201015     DOI: 10.3892/ijo.2014.2645

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  Downregulation of FoxM1 inhibits cell growth and migration and invasion in bladder cancer cells.

Authors:  Xinping Yang; Yuanyuan Shi; Jingzhe Yan; Haitao Fan
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

2.  MicroRNA-320 suppresses cervical cancer cell viability, migration and invasion via directly targeting FOXM1.

Authors:  Can Shi; Zhenyu Zhang
Journal:  Oncol Lett       Date:  2017-07-21       Impact factor: 2.967

3.  Association between FOXM1 and hedgehog signaling pathway in human cervical carcinoma by tissue microarray analysis.

Authors:  Hong Chen; Jingjing Wang; Hong Yang; Dan Chen; Panpan Li
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

4.  Short hairpin RNA- mediated gene knockdown of FOXM1 inhibits the proliferation and metastasis of human colon cancer cells through reversal of epithelial-to-mesenchymal transformation.

Authors:  KanKan Yang; LinHua Jiang; You Hu; Jing Yu; HenFeng Chen; YiZhou Yao; XinGuo Zhu
Journal:  J Exp Clin Cancer Res       Date:  2015-05-03

5.  FoxM1 and β-catenin predicts aggressiveness in Middle Eastern ovarian cancer and their co-targeting impairs the growth of ovarian cancer cells.

Authors:  Poyil Pratheeshkumar; Sasidharan Padmaja Divya; Sandeep Kumar Parvathareddy; Norah M Alhoshani; Ismail A Al-Badawi; Asma Tulbah; Fouad Al-Dayel; Abdul K Siraj; Khawla S Al-Kuraya
Journal:  Oncotarget       Date:  2017-12-16

6.  The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer.

Authors:  Karan Ulhaka; Kanyanatt Kanokwiroon; Mattaka Khongkow; Rassanee Bissanum; Thanaporn Khunpitak; Pasarat Khongkow
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

7.  Cytotoxic activities of Hypericum perforatum L. extracts against 2D and 3D cancer cell models.

Authors:  Ivana Z Matić; Sercan Ergün; Marija Đorđić Crnogorac; Sema Misir; Yüksel Aliyazicioğlu; Ana Damjanović; Hurija Džudžević-Čančar; Tatjana Stanojković; Kalbiye Konanç; Nina Petrović
Journal:  Cytotechnology       Date:  2021-04-01       Impact factor: 2.040

8.  Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis.

Authors:  Jie Ma; Guangwei Qi; Ji Xu; Haibing Ni; Wulin Xu; Guoqing Ru; Zhongsheng Zhao; Wenjuan Xu; Xujun He
Journal:  Oncol Lett       Date:  2017-10-04       Impact factor: 2.967

Review 9.  Angioregulatory microRNAs in Colorectal Cancer.

Authors:  Mohammad Hasan Soheilifar; Michael Grusch; Hoda Keshmiri Neghab; Razieh Amini; Hamid Maadi; Massoud Saidijam; Zhixiang Wang
Journal:  Cancers (Basel)       Date:  2019-12-26       Impact factor: 6.639

10.  Silencing of FoxM1 blocks growth, migration and invasion of papillary thyroid carcinoma cells.

Authors:  Xiaotao Wang; Yongkui Zhao; Mingxin Cui; Jianli Chen; Wenbin Cao; Guanghua Yang; Qianyu Liu; Guozhi Zhang
Journal:  Oncol Lett       Date:  2019-11-18       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.